Health News
SANOFI-AVENTIS NEWS
Solid growth in the second quarter
-- Net sales: euro 6,689m, up 5.2% on a comparable basis (down 3.6% on a
reported basis)
- 4.1% growth for the Pharmaceuticals business
- Good performance from flagship products
- Resilience from the rest of the portfolio: net sales up 0.8%
- Strong growth in Vaccines (up 17.1% on a comparable basis)
- Double-digit growth in emerging markets
-- 11.2% growth in operating income - current(1) excluding currency
effects
- Ongoing cost control measures, and further improvement in the ratio
of selling and general expenses to net sales (26.7% vs. 27.8%)
-- Adjusted net income excluding selected items: euro 1,753m, up 0.7% (up
3.9% per share)
Acquisitions to enlarge our market presence
-- Competing tender offer for Zentiva
-- Agreement to acquire a nutraceuticals/OTC business in Australia
-- Recommended offer by Sanofi Pasteur for Acambis
Research and Development
-- Multaq(R) submitted in Europe and the United States
-- Approval of the Pentacel(R) pediatric vaccine in the United States at
end June
Increase in 2008 Guidance
Barring major adverse events, sanofi-aventis expects 2008 full-year
adjusted EPS excluding selected items(1) to grow around 8%, calculated at
constant
Sensitivity to the euro/dollar exchange rate is estimated at 0.5% of
growth for a
2008 second-quarter and first-half net sales
Unless otherwise indicated, all sales growth figures in this press release are stated on a comparable basis.
Sanofi-aventis generated second-quarter net sales of
First-half net sales rose by 2.9% to
Net sales by business segment - Pharmaceuticals
Second-quarter net sales for the pharmaceuticals business grew 4.1% to
reach
First-half net sales for the pharmaceuticals business were up 2.3% at
Change on a Change on a
Q2 2008 comparable H1 2008 comparable
euro million net sales basis net sales basis
Lovenox(R) 637 +4.6% 1,354 +12.9%
Plavix(R) 664 +8.5% 1,326 +13.4%
Lantus(R) 576 +27.2% 1,133 +28.9%
Taxotere(R) 503 +14.1% 987 +13.7%
Eloxatin(R) 326 -5.0% 668 -5.5%
Aprovel(R) 311 +18.7% 600 +14.9%
Copaxone(R) 103 +24.1% 420 +19.7%
Stilnox(R)/Ambien(R)
/Ambien CR(R)/Myslee(R) 191 -22.4% 401 -50.1%
Allegra(R) 171 -5.0% 375 +1.6%
Tritace(R) 137 -17.0% 275 -27.1%
Amaryl(R) 95 -5.0% 187 -2.6%
Xatral(R) 85 +7.6% 168 +6.3%
Depakine(R) 81 +3.8% 163 +7.2%
Actonel(R) 87 +8.7% 162 +3.8%
Nasacort(R) 60 -22.1% 130 -12.8%
TOP 15 4,027 +5.8% 8,349 +3.7%
Rest of the portfolio 2,005 +0.8% 4,072 -0.5%
Total Pharmaceuticals 6,032 +4.1% 12,421 +2.3%
Comments by product
Lovenox(R), the leading low molecular weight heparin on the market, reported moderate growth in net sales in the second quarter.
In
In
The impact of heparin short supply neutralized over H1 2008 period,
Lovenox sales were up 12.9% at
Net sales of Lantus(R), the world's leading insulin brand, rose by 27.2%
in the second quarter to
The results of the TULIP study, presented to the American Diabetes Association (ADA) in June, confirmed the importance of promptly initiating insulin treatment when patients with type 2 diabetes are unable to achieve recommended glycemic targets with diet, exercise and oral diabetes medications alone. In this study, 66% of patients who began treatment with Lantus(R) achieved A1C of <7%, the ADA's recommended target for glycemic control, while only 38% of patients from the lifestyle management arm were able to achieve the recommended target levels.
Taxotere(R) again achieved double-digit growth in the second quarter,
across all three geographical regions. In
Also in May, the results from the AVADO study presented to the American Society of Clinical Oncology (ASCO) showed the benefits of combining Taxotere(R) and Avastin(R) as a first-line treatment for women with HER2 negative metastatic breast cancer.
Ambien CR(R) posted second-quarter net sales of
In
In June, results from a new study presented at the SLEEP 2008 Annual Meeting of the Associated Professional Sleep Societies (APSS) demonstrated that Ambien CR(R) 12.5mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with comorbid insomnia and major depressive disorder who were administered a Selective Serotonin Reuptake Inhibitor (SSRI) for depression.
In
In May, the United States Food and Drug Administration (FDA) approved a supplemental new drug application to include six-year overall survival analysis from the MOSAIC trial in the Eloxatin(R) prescribing information. The trial results showed that after a median follow-up of six years, Stage III colon cancer patients treated with FOLFOX4 (Eloxatin(R) + 5-FU/LV) had a 20% reduction in the risk of dying compared to those treated with standard chemotherapy alone. The new prescribing information also includes five-year disease free survival data in Stage III colon cancer patients treated following surgery to remove the primary tumor.
Net sales of Acomplia(R) reached
Positive results from ARPEGGIO, the first clinical trial on the administration of rimonabant to patients with type 2 diabetes not adequately controlled with insulin therapy, were presented to the American Diabetes Association (ADA) in June.
Xyzal(R), a new prescription oral antihistamine launched by sanofi-aventis
and UCB in
Worldwide presence of Plavix(R) / Iscover(R)
Change on a Change on a
comparable comparable
euro million Q2 2008 basis H1 2008 basis
Europe 469 +5.9% 930 +5.1%
United States 774 +18.7% 1,552 +30.4%
Other Countries 228 +20.0% 459 +25.8%
TOTAL 1,471 +14.5% 2,941 +20.5%
In
In
Sanofi-aventis became aware on
In the rest of the world, Plavix(R) recorded growth of 20% in the quarter
and 25.8% in the first half, strengthened by its performance in
Worldwide presence of Aprovel(R)/ Avapro(R)/ Karvea(R)
Change on a Change on a
comparable comparable
euro million Q2 2008 basis H1 2008 basis
Europe 255 +10.9% 500 +9.6%
United States 117 +7.3% 236 +7.8%
Other Countries 127 +32.3% 235 +27.7%
TOTAL 499 +14.7% 971 +13.0%
Second-quarter worldwide sales of Aprovel(R)/Avapro(R)/Karvea(R) were up
14.7% at
Net sales by business segment - Human Vaccines
Second-quarter consolidated net sales for the Human Vaccines business rose
by 17.1% to
Net sales of influenza vaccines increased 78.2% in the quarter to
Adult booster vaccines also achieved strong growth, of 18.1%, due
primarily to the performance of Adacel(TM) (adult and adolescent tetanus-
diphtheria-pertussis booster), which increased 33.2% in the quarter to
Net sales of Menactra(R) rose by 1.9% in the second quarter to
Pentacel(R), the first 5-in-1 pediatric combination vaccine to protect
against diphtheria, tetanus, pertussis, polio and haemophilus influenzae type
b, was approved in
First-half consolidated net sales for the Human Vaccines business were up
10.1% at
Change on a Change on a
Q2 2008 comparable H1 2008 comparable
euro million net sales basis net sales basis
Influenza Vaccines* 155 +78.2% 200 +38.9%
Polio/Pertussis/Hib
Vaccines 187 +5.1% 355 +1.1%
Meningitis/Pneumonia
Vaccines 109 +4.8% 225 +22.3%
Adult Booster Vaccines 98 +18.1% 200 +1.5%
Travel & Other Endemics
Vaccines 78 0.0% 157 +1.3%
Other Vaccines 30 -3.2% 68 +7.9%
TOTAL 657 +17.1% 1,205 +10.1%
*seasonal and pandemic influenza vaccines
Second-quarter sales at Sanofi Pasteur MSD, the joint venture with Merck &
Co in
First-half sales for Sanofi Pasteur MSD were up 60.1% on a reported basis
at
In June, Sanofi Pasteur inaugurated a new vaccine production facility at
Val de Reuil,
Net sales by geographic region
Change on a Change on a
Q2 2008 comparable H1 2008 comparable
euro million net sales basis net sales basis
Europe 3,045 +1.0% 6,132 +0.1%
United States 1,979 +6.6% 4,149 +1.5%
Other Countries 1,665 +12.0% 3,345 +10.6%
TOTAL 6,689 5.2% 13,626 2.9%
In
In
Net sales in the Other Countries region rose by 12.0% in the second quarter and by 10.6% in the first half.
Adjusted consolidated income statement
Second quarter of 2008
In the second quarter of 2008, sanofi-aventis generated net sales of
Gross profit was
Research and development expenses fell by 0.9%, but rose by 3.4% after excluding exchange rate effects.
Selling and general expenses fell by 7.4% (or by 1.9% excluding exchange
rate effects) to
Other current operating income, net of expenses totaled
Operating income - current(1) was 3.1% higher at
The 2008 second-quarter financial statements include restructuring costs
of
An impairment loss of
Net financial expenses were
The effective tax rate was 29.6%, compared with 30.7% for the second quarter of 2007.
The share of profits from associates was
Minority interests came to
Adjusted net income came to
Adjusted net income excluding selected items was
Expressed in
First half of 2008
In the first half of 2008, sanofi-aventis generated net sales of
Gross profit was
Research and development expenses were virtually unchanged (down 0.1%) at
Selling and general expenses totaled
Operating income - current was 2.5% lower at
The 2008 first-half financial statements include restructuring costs of
The effective tax rate was 29.6%. In 2007, income tax expense included a
net gain of
The share of profits from associates was
Minority interests totaled
Adjusted net income was down 8.6% at
Adjusted earnings per share (adjusted EPS) was
Adjusted net income excluding selected items was
Expressed in
Consolidated statement of cash flows and balance sheet as of
Operating cash flow before changes in working capital for the first half
of 2008 was
Working capital needs increased by
Investing activities generated a net cash outflow of
After the dividend payout of
Net debt stood at
Gearing was 13.5% as of
Increase in 2008 Guidance(4)
Barring major adverse events, sanofi-aventis expects 2008 full-year
adjusted EPS excluding selected items to grow around 8%, calculated at
constant
Sensitivity to the euro/dollar exchange rate is estimated at 0.5% of
growth for a
Research and Development
The R&D results highlights of the second quarter of 2008 include the
exceptional results of the ATHENA trial, evaluating the efficacy of Multaq(R)
on morbidity/mortality of patients with atrial fibrillation. Registration
dossier was submitted to the healthcare authorities in
Our ongoing portfolio rationalization program, designed to target resources on the most promising projects, led to the discontinuation during the quarter of some projects judged to have an inadequate risk/benefit profile.
The main advances in our portfolio during the quarter are described below:
Cardiovascular/Thrombosis
Multaq(R): The results of the ATHENA morbidity/mortality trial were
presented at the 29th Annual Scientific Sessions of the American Heart Rhythm
Society (HRS) in
For the first time in twenty years of pharmaceutical research in atrial fibrillation, a treatment has shown a significant decrease in the risk of cardiovascular death by 30% (p = 0.03) on top of standard therapy, including rate control and antithrombotic drugs. Multaq(R) also significantly decreased the risk of arrhythmic death by 45% (p=0.01). First cardiovascular hospitalization was reduced by 25% (p = 9.10(-9)) versus the placebo group.
Registration dossier for Multaq(R) was submitted at the end of June in
Idrabiotaparinux (biotinylated idraparinux) is a long-acting selective neutralizable factor Xa coagulation inhibitor, administered by weekly subcutaneous injection.
The results of the EQUINOX bioequipotency study show that idrabiotaparinux has a similar pharmacodynamic profile to idraparinux, as well as an efficacy and safety profile in line with those obtained with idraparinux in the Van Gogh study (which evaluated idraparinux in the treatment of deep vein thrombosis). In addition, after 6 months of treatment, neutralization of the anti-Xa effect of idrabiotaparinux by avidin is obtained very rapidly with no rebound effect.
Enrolment to two large-scale phase III trials is ongoing. More than half of the 3,200 patients for the CASSIOPEA pulmonary embolism trial have been recruited to date. Enrolment of patients to the BOREALIS-AF trial is on track. This trial is designed to assess the efficacy of biotinylated idraparinux versus anti-vitamin K in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Filing for approval in this indication is scheduled for 2011.
AVE5026 is a powerful anti-coagulant (ultra low weight molecular heparin) with pharmacodynamic properties that go beyond anti-Xa factor activity. Because of its subcutaneous mode of administration, it is not associated with differences in bioavailability.
Enrolment to the 7 trials in the phase III program, which will include over 10,000 patients, is under way.
Filing for approval in the first set of indications (prevention of venous thromboembolic events in patients requiring hip or knee replacement, or undergoing hip fracture surgery or abdominal surgery, or receiving chemotherapy) is scheduled for 2010, followed by a subsequent filing (prevention of thromboembolic events in medical patients) in 2011.
NV1FGF is a highly innovative gene therapy approach. Enrolment to the TAMARIS phase III trial, which will evaluate the product's efficacy in preventing amputations in patients suffering from critical lower limb ischemia, has started with 120 active centers. Filing for approval in this indication is scheduled for 2010.
It has been decided to discontinue the development of ilepatril (AVE 7688) and SL65.0472.
Oncology
Aflibercept (VEGF Trap) is being developed under an alliance with Regeneron. It has a unique mechanism of action and its properties, when compared with monoclonal antibodies, give it the potential to be an anti-angiogenesis agent with a broader spectrum of activity.
Results from a randomized double-blind study involving 215 women with advanced ovarian cancer treated with a 2 mg/kg or 4 mg/kg dose of aflibercept every two weeks have been presented to the American Society of Clinical Oncology (ASCO).
The study showed clear evidence of a response as measured by RECIST (Response Evaluation Criteria in Solid Tumors) and CA-125. According to the IRC (Independent Review Committee), RECIST response rates were 4.6% in patients receiving the 4 mg/kg dose and 0.9% in those receiving the 2 mg/kg dose. However, the study did not achieve its primary endpoint of demonstrating that patients in either arm of the study achieved an IRC-assessed response of at least 5%.
The CA-125 response, an important marker of tumoral activity in ovarian cancer, was a secondary endpoint of the study. Response rates, defined as at least a 50% reduction in CA-125 antigen levels, were 11.6% in the evaluable patients treated with 4 mg/kg and 11.5% in the evaluable patients treated with 2 mg/kg.
Enrolment to the 4 pivotal phase III studies is on track:
-- the VENICE study is evaluating aflibercept as a first-line treatment
for hormone refractory prostate cancer (in combination with
Taxotere(R)/prednisone), target patient number 1,240;
-- the VELOUR study is evaluating aflibercept as a second-line treatment
for colorectal cancer (in combination with the FOLFIRI regime), target
patient number 1,200;
-- the VITAL study is evaluating aflibercept as a second-line treatment
for non small cell lung cancer (in combination with Taxotere(R)),
target patient number 900;
-- the VANILLA study is evaluating aflibercept as a first-line treatment
for pancreatic cancer (in combination with gemcitabine), target patient
number 630.
In addition, a phase II study of aflibercept as a first-line treatment for metastatic colorectal cancer is due to begin in the second half of 2008.
Based on the 1,600 patients already treated, the undesirable side-effects of aflibercept have been consistent with those expected for this class of anti-angiogenesis agents (hypertension, proteinuria). The reported incidence of bowel perforations has been low.
AVE8062 (licensed from Ajinomoto) is an agent that induces rapid destruction of intra-tumoral micro-vessels. Enrolment to a phase III study evaluating AVE8062 as a second-line treatment for advanced sarcoma has begun. Filing in this indication is scheduled for 2011.
In July, the Data Safety Monitoring Board (DSMB) for TRIST study of Trovax(R) (partnership with Oxford Biomedica) in renal cancer has recommended that patients vaccinations in this study be discontinued.
On
Central Nervous System
Eplivanserin is a compound in a new class, 5HT2-A antagonists, intended to treat sleep disorders. It improves the quality of sleep by reducing the number and duration of WASO (Wake time After Sleep Onset) events in patients with fragmented sleep patterns, with no residual effects reported to date.
Submissions for the approval of eplivanserin are due to be filed with the authorities in the fourth quarter of 2008.
Saredutant: Results from the MAGENTA study, evaluating the maintenance of the effects of saredutant in the treatment of major depressive disorders, confirmed the product's good long-term safety profile. However, the MAGENTA study also showed that relapse was not significantly reduced versus placebo when patients who had responded to saredutant after 3 months had their treatment extended to 12 months.
Analysis of all other saredutant short term studies revealed a benefit for patients with major depressive disorders based on the HAM-D scale.
The decision on submitting saredutant for regulatory approval will depend on the results of two ongoing trials assessing the product in combination with the selective serotonin reuptake inhibitors (SSRIs) escitalopram and paroxetine, which are due to be completed in the first half of 2009.
Teriflunomide is a potential oral treatment for multiple sclerosis, with a targeted efficacy profile similar to interferons on relapse and progression of disability, but with a better safety. Enrolment of the 1,080 patient population in the TEMSO phase III placebo-controlled trial evaluating teriflunomide as monotherapy is now complete.
It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).
Metabolism
AVE0010 is a novel injectable anti-diabetic in the GLP-1 receptor agonist class. Results from the phase IIb study of AVE0010, presented to the American Diabetes Association (ADA), showed that treatment with AVE0010 was well tolerated and significantly improved glycemic control, compared to placebo in type 2 diabetes patients who were unable to achieve adequate control with metformin as monotherapy. The once-daily dose regimen gave a marked dose-response effect, with a reduction in HbA1c comparable with that of a twice-daily regimen. Treatment with AVE0010 was also accompanied by weight loss, a reduction in post-prandial glycemia, and good gastro-intestinal tolerance.
A large phase III programme involving over 3,000 patients began in the second quarter. This programme is evaluating a once-daily injection of AVE0010 on top of the main existing treatments (metformin, sulfonylurea, insulin, pioglitazone), and also includes a comparison with exenatide and a monotherapy study. Submission for approval is scheduled for 2010, but this date may change due to new FDA pre-conditions in this indication. A phase I study evaluating a prolonged release formulation is under way.
Rimonabant: The development program in type 2 diabetes is ongoing.
Results from ARPEGGIO, the first clinical trial on the administration of rimonabant to patients with type 2 diabetes not adequately controlled with insulin therapy, were presented to the American Diabetes Association (ADA) in June. Rimonabant significantly improved HbA1c by 0.89% from the baseline value, and by 0.64% over the control group (p<0.0001). Glucose control was three times more pronounced when rimonabant was added than with insulin treatment and lifestyle advice alone.
Enrolment of the 17,000 patient population to the CRESCENDO morbidity-mortality trial is now complete, and the results are expected in 2011.
AVE5530 is a cholesterol absorption inhibitor. Results from phase IIb trials showed a significant reduction in LDL at different doses, confirming the potential benefits of this product. Its mode of action, with limited systemic absorption relative to competing products, gives it a potential to avoid drug interaction with good tolerance. AVE5530 has the potential to be used as monotherapy or in combination with statins. A phase III program comprising four trials has started. Submission for approval is scheduled for the second half of 2010, both as monotherapy and in fixed combination with a statin.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in
Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include product development, product potential projections and estimates and
their underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future events, operations,
products and services, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects,"
"anticipates," "believes," "intends," "estimates," "plans" and similar
expressions. Although sanofi-aventis management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of sanofi-aventis, that could cause actual
results and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties inherent
in research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMEA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as their
decisions regarding labeling and other matters that could affect the
availability or commercial potential of such products candidates, the absence
of guarantee that the products candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives as well as those discussed or identified in the public filings
with the SEC and the AMF made by sanofi-aventis, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements"
in sanofi-aventis' annual report on Form 20-F for the year ended
Contact:
Recent Events
May 14, 2008 Shareholders' Annual General Meeting:
- Distribution of a net dividend of euro 2.07 per share (up
18.3%)
- Approval of the appointment of thirteen directors on the
expiry of the mandates of existing Board members at the
end of the AGM
Board meeting following the AGM:
- Reappointment of the Chairman of the Board of Directors
for a two-year term
- Authorization for the company to repurchase its own shares
up to a maximum of euro 3bn, valid until the next AGM
May 15, 2008 Announcement that the U.S. Court of Appeals for the Federal
Circuit had affirmed the decision by the U.S. District Court
in the sanofi-aventis Lovenox(R) patent infringement suit
against Amphastar and Teva.
May 15, 2008 Announcement of very positive results from the ATHENA trial,
showing that Multaq(R) significantly reduces the risk of
cardiovascular hospitalization or death by 24% in patients
with atrial fibrillation or atrial flutter.
May 21, 2008 Release of an updated clinical development program for
aflibercept, including results from a Phase II trial in
advanced ovarian cancer.
May 27, 2008 Announcement that in women with high-risk node-negative
early stage breast cancer (GEICAM 9805/Target-0 study),
adjuvant treatment based on Taxotere(R) was associated with
a significant improvement in disease free survival compared
to a standard regimen.
May 28, 2008 Announcement that the FDA had approved a supplemental new
drug application to include six-year overall survival
analysis from the MOSAIC trial in the Eloxatin(R)
prescribing information.
May 28, 2008 Statement by sanofi-aventis on third-party clopidogrel
registration applications in Germany.
June 2, 2008 Announcement by sanofi-aventis and Oxford Biomedica of
encouraging results from phase II trials of Trovax(R) in
metastatic kidney cancer.
June 7, 2008 Release at the ADA of a study demonstrating the efficacy of
Apidra(R) in the treatment of children and adolescents with
type 1 diabetes.
June 7, 2008 Presentation to the ADA of results of a dose research study
on the novel injectable anti-diabetic AVE0010, a GLP-1
receptor agonist.
June 7, 2008 Presentation to the ADA of results from the TULIP study,
confirming the importance of promptly initiating insulin
treatment when patients with type 2 diabetes are unable to
achieve recommended glycemic targets with diet, exercise and
oral diabetes medications alone.
June 10, 2008 Announcement of results from a new study demonstrating that
Ambien CR(R) relieves insomnia and improves next-day
functioning in patients with associated major depressive
disorders.
June 10, 2008 Presentation to the ADA of a 5-year safety study examining
the effect of Lantus(R) on the progression of retinopathy in
patients with type 2 diabetes.
June 10, 2008 Presentation to the ADA of results from ARPEGGIO, the first
clinical trial on the administration of rimonabant to
patients with type 2 diabetes not adequately controlled with
insulin therapy.
June 16, 2008 Announcement of commitment by sanofi-aventis to donate 60
million doses of H5N1 vaccine to the World Health
Organization over 3 years for the establishment of an H5N1
vaccine global stockpile.
June 18, 2008 Announcement by sanofi-aventis of its intention to make a
competing bid of CSK1,050 per share for Zentiva.
June 23, 2008 Announcement that the FDA had approved Pentacel(R), sanofi
pasteur's new pediatric combination vaccine.
June 25, 2008 Inauguration of a state-of-the-art vaccine production
facility in France.
July 11, 2008 Announcement by Oxford Biomedica that the DSMB for the TRIST
study had recommended discontinuing the vaccination of
patients taking part in the study with Trovax(R).
July 11, 2008 Opening of the tender offer for Zentiva.
July 17, 2008 Announcement of the signature of a 3-year collaboration
agreement with the Division of Allergy and Clinical
Immunology of the Johns Hopkins University School of
Medicine, Baltimore, USA.
July 18, 2008 Announcement of the termination of the agreement with Taiho
Pharmaceutical on the development and commercialization of
S-1.
July 21, 2008 Announcement of the signature of an agreement with Primary
Health Care to acquire Symbion Consumer, its Australian
nutraceuticals and OTC business.
July 21, 2008 Two Regimens Including Lantus(R) and Apidra(R) resulted
in Significant Reductions in A1c in Patients with Type 2
Diabetes, Whatever the Algorithm Used
July 22, 2008 Announcement of the approval by European Commission of
Apidra(R) for Treatment of Children & Adolescents with
Diabetes
July 25, 2008 Announcement of a recommended offer for Acambis plc
July 29, 2008 Two decisions of the German administrative court in Cologne
to order immediate enforcement of German marketing
authorizations held by Yes and by a subsidiary of Ratiopharm
for their clopidogrel besylate products
Financial Timetable
October 31,
2008 2008 third-quarter net sales and results
(1) U.S. dollar figures obtained by translating euro-denominated figures
at the average exchange rate for the period (Q2 2008: 1.562, Q2 2007:
1.348; H1 2008: 1.531, H1 2007: 1.329)
(2) Excluding net sales of Ambien(R) IR in the United States in Q1 2007
and Q1 2008, and of Eloxatin(R) in Europe in H1 2007 and H1 2008
(3) Excluding net sales of Ambien(R) IR in the United States in the first
quarter of 2007 and 2008
(4) Compared with adjusted EPS excluding selected items of euro 5.17 for
2007
SOURCE sanofi-aventis
Browse by Category
- Dermatology
- General
- Pharmaceutical
- Weight Loss
- Senior Health
- Men's Health
- Women's Health
- Children's Health
Browse by Condition
- Acne
- Acne Scars
- ADHD / ADD
- Age Spots
- AIDS
- Alcohol Abuse
- Allergies
- Alzheimer's Disease
- Anxiety
- Arthritis
- Atrial Fibrillation
- Autism
- Back Pain
- Bed Wetting
- Binge Eating Disorder
- Bipolar Disorder
- Birth Control
- Bladder Cancer
- Brain and Nervous
- Brain Cancer
- Breast Cancer
- Bruxism
- Bulimia Nervosa
- Cancer
- Cellulite
- Cholesterol Management
- Cold
- Colorectal Cancer
- Crohn's Disease
- Depression
- Diabetes
- Digestive Disorders
- Ear Infection
- Epilepsy
- Erectile Dysfunction
- Eye Health
- Fibromyalgia
- Flu
- Food Poisoning
- Freckles
- Genital Herpes
- Genital Warts
- GERD
- Headaches
- Healthy Aging
- Heart Disease
- Heart Failure
- Heart Health
- Heartburn
- Hemorrhoids
- Hepatitis
- HIV
- HPV
- Hyperhidrosis
- Hypersomnia
- Hypertension
- IBD
- Incontinence
- Infertility & Reproduction
- Insomnia
- Irritable Bowel Syndrome (IBS)
- Jet Lag
- Knee Pain
- Liver Spots
- Lung Cancer
- Lupus
- Macular Degeneration
- Medicare
- Melanoma
- Melasma
- Menopause
- Mental Health
- Migraines
- Multiple Sclerosis
- Narcolepsy
- Night Sweats
- Night Terrors
- Non-Hodgkin's Lymphoma
- OAB
- Obesity
- Oral Health
- Osteoarthritis
- Osteoporosis
- Ovarian Cancer
- Pain Management
- Panic Disorder
- Parasomnia
- Parkinson's Disease
- Periodic Limb Movement Disorder (PLMD)
- Prostate Cancer
- Psoriasis
- Restless Leg Syndrome (RLS)
- Rheumatoid Arthritis
- Rosacea
- Schizophrenia
- Sexual Conditions
- Sexual Health
- Shingles
- Skin Cancer
- Skin Problems
- Skin Treatments
- Sleep Apnea
- Sleep Disorders
- Sleep Paralysis
- Sleep Talking
- Sleep Walking
- Smoking Cessation
- Snoring
- Spider Veins
- Stroke
- Sun Spots
- Varicose Veins
- Wrinkles
